Facebook
Twitter
Telegram
Report an ErrorClovis Oncology Balance Sheet 2011-2024 | CLVS
Annual Balance Sheet Clovis Oncology
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
293 M | 370 M | 653 M | 652 M | -82.3 M | 115 M | 251 M | -195 M | -323 M | -144 M | -138 M |
Long Term Debt |
437 M | 546 M | 680 M | 575 M | 282 M | 281 M | 280 M | 288 M | - | - | - |
Long Term Debt Current |
- | - | - | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | 579 M | 711 M | 591 M | 286 M | 303 M | 337 M | 407 M | 131 M | 338 K | 656 K |
Total Current Liabilities |
125 M | 185 M | 133 M | 126 M | 81.5 M | 65.6 M | 75.6 M | 47.8 M | 21 M | 12.2 M | - |
Total Liabilities |
752 M | 764 M | 844 M | 717 M | 368 M | 368 M | 413 M | 455 M | 152 M | 12.5 M | 11.7 M |
Deferred Revenue |
- | - | - | - | - | - | - | - | - | - | - |
Retained Earnings |
-2.88 B | -2.61 B | -2.24 B | -1.84 B | -1.48 B | -1.13 B | -782 M | -429 M | -269 M | -184 M | -110 M |
Total Assets |
473 M | 606 M | 670 M | 864 M | 735 M | 365 M | 713 M | 786 M | 650 M | 146 M | 143 M |
Cash and Cash Equivalents |
143 M | 240 M | 162 M | 222 M | 464 M | 216 M | 279 M | 483 M | 323 M | 144 M | 138 M |
Book Value |
-279 M | -159 M | -174 M | 146 M | 368 M | -3.63 M | 301 M | 332 M | 498 M | 133 M | 132 M |
Total Shareholders Equity |
-279 M | -159 M | -174 M | 146 M | 368 M | -3.63 M | 301 M | 332 M | 498 M | 133 M | 132 M |
All numbers in USD currency
Quarterly Balance Sheet Clovis Oncology
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
- | 443 M | 438 M | 437 M | 437 M | 436 M | 436 M | 435 M | 435 M | 435 M | 435 M | 435 M | 645 M | 645 M | 645 M | 645 M | 588 M | 575 M | 575 M | 575 M | 282 M | 282 M | 282 M | 282 M | 281 M | 281 M | 281 M | 281 M | 280 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 150 K | 211 K | 270 K | 338 K | 408 K | 338 K | 338 K | 656 K | 656 K | 656 K | 656 K |
Total Liabilities |
- | 765 M | 761 M | 755 M | 752 M | 733 M | 779 M | 770 M | 764 M | 764 M | 764 M | 764 M | 844 M | 844 M | 844 M | 844 M | 717 M | 717 M | 717 M | 717 M | 368 M | 368 M | 368 M | 368 M | 368 M | 368 M | 368 M | 368 M | 413 M | 413 M | 413 M | 413 M | 446 M | 455 M | 455 M | 455 M | 152 M | 152 M | 152 M | 152 M | 12.5 M | - | - | - | - | - | - | - |
Deferred Revenue |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Retained Earnings |
- | -3.06 B | -3.01 B | -2.94 B | -2.88 B | -2.81 B | -2.75 B | -2.68 B | -2.61 B | -2.61 B | -2.61 B | -2.61 B | -2.24 B | -2.24 B | -2.24 B | -2.24 B | -1.84 B | -1.84 B | -1.84 B | -1.84 B | -1.48 B | -1.48 B | -1.48 B | -1.48 B | -1.13 B | -1.13 B | -1.13 B | -1.13 B | -782 M | -782 M | -782 M | -782 M | -429 M | -429 M | -429 M | -429 M | -269 M | -269 M | -269 M | -269 M | - | - | - | - | - | - | - | - |
Total Assets |
- | 347 M | 393 M | 452 M | 473 M | 508 M | 572 M | 549 M | 606 M | 606 M | 606 M | 606 M | 670 M | 670 M | 670 M | 670 M | 864 M | 864 M | 864 M | 864 M | 735 M | 735 M | 735 M | 735 M | 365 M | 365 M | 365 M | 365 M | 713 M | 713 M | 713 M | 713 M | 777 M | 786 M | 786 M | 786 M | 650 M | 650 M | 650 M | 650 M | 146 M | 146 M | 146 M | 146 M | 143 M | 143 M | 143 M | 143 M |
Cash and Cash Equivalents |
- | 58.3 M | 94.6 M | 122 M | 143 M | 172 M | 230 M | 191 M | 240 M | 240 M | 240 M | 240 M | 162 M | 162 M | 162 M | 162 M | 222 M | 222 M | 222 M | 222 M | 464 M | 464 M | 464 M | 464 M | 216 M | 216 M | 216 M | 216 M | 279 M | 279 M | 279 M | 279 M | 483 M | 483 M | 483 M | 483 M | 323 M | 323 M | 323 M | 323 M | 144 M | 144 M | 144 M | 144 M | 138 M | 138 M | 138 M | 138 M |
Book Value |
- | -418 M | -368 M | -303 M | -279 M | -225 M | -207 M | -221 M | -159 M | -159 M | -159 M | -159 M | -174 M | -174 M | -174 M | -174 M | 146 M | 146 M | 146 M | 146 M | 368 M | 368 M | 368 M | 368 M | -3.63 M | -3.63 M | -3.63 M | -3.63 M | 301 M | 301 M | 301 M | 301 M | 332 M | 332 M | 332 M | 332 M | 498 M | 498 M | 498 M | 498 M | 133 M | 146 M | 146 M | 146 M | 143 M | 143 M | 143 M | 143 M |
Total Shareholders Equity |
- | -418 M | -368 M | -303 M | -279 M | -225 M | -207 M | -221 M | -159 M | -159 M | -159 M | -159 M | -174 M | -174 M | -174 M | -174 M | 146 M | 146 M | 146 M | 146 M | 368 M | 368 M | 368 M | 368 M | -3.64 M | -3.63 M | -3.63 M | -3.63 M | 301 M | 301 M | 301 M | 301 M | 332 M | 332 M | 332 M | 332 M | 498 M | 498 M | 498 M | 498 M | 133 M | 133 M | 133 M | 133 M | 132 M | 132 M | 132 M | 132 M |
All numbers in USD currency